Overview

A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of Bortezomib plus GDP in the treatment of non-GCB DLBCL patients.
Phase:
Phase 2
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
BB 1101
Bortezomib
Cisplatin
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Gemcitabine